Tag: injection

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15^th, 2025, to discuss the company’s financial results for the second quarter ended June 30, 2025, as well as the company’s corporate progress and other developments.

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Crown Laboratories, a Revance Company, Ranks No. 3,991 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies

With Three-Year Revenue Growth of 91%, this Marks the Company's 12th Appearance on the List NASHVILLE, Tenn., Aug. 12, 2025 /PRNewswire/ -- Crown Laboratories, Inc., a...

NGEx Reports Q2 2025 Results; Porphyry and High-grade Gold Discoveries at Lunahuasi; Plan to Spin-out Royalties to Shareholders

VANCOUVER, BC, Aug. 11, 2025 /CNW/ - NGEx Minerals Ltd. ("NGEx Minerals" "NGEx" or the "Company") (TSX: NGEX) (OTCQX: NGXXF) is pleased to report...

Hillenbrand Reports Fiscal Third Quarter 2025 Results

Revenue of $599 million decreased 24% compared to prior year; pro forma revenue decreased 10%GAAP EPS of $0.03 increased from $(3.53) in the prior...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Franco-Nevada Reports Record Q2 2025 Results

Acquisitions Increase Growth Outlook (in U.S. dollars unless otherwise noted) TORONTO, Aug. 9, 2025 /PRNewswire/ - "I am very pleased with our record financial results this...

Hugel launches botulinum toxin Letybo in Malaysia

- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium...

GLP-1 Plus by Advanced BioNutritionals: 2025 DHB Breakthrough Ignites Interest in Non-Injection Hunger and Weight Trends

GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.

GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Tencent Cloud, UXSoft, and BAPE Hong Kong Limited Collaborate to Power Global Retail Infrastructure for A Bathing Ape®

PIS Showcases Global Growth Strategy & Expansion Plan at Posidonia 2026

Age is just a Number. Mobility is a Choice.